The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species  by Dicks, Matthew D.J. et al.
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a  b  s  t  r  a  c  t
Adenovirus  vaccine  vectors  generated  from  new  viral  serotypes  are  routinely  screened  in  pre-clinical
laboratory  animal  models  to  identify  the  most  immunogenic  and  efﬁcacious  candidates  for  further  eval-
uation  in  clinical  human  and  veterinary  settings.  Here,  we  show  that  studies  in  a laboratory  species  do
not  necessarily  predict  the  hierarchy  of vector  performance  in  other  mammals.  In mice, after  intra-
muscular  immunization,  HAdV-5  (Human  adenovirus  C)  based  vectors  elicited  cellular  and  humoral
adaptive  responses  of higher  magnitudes  compared  to the  chimpanzee  adenovirus  vectors  ChAdOx1
and  AdC68  from  species  Human  adenovirus  E. After  HAdV-5  vaccination,  transgene  speciﬁc  IFN-+ CD8+
T  cell  responses  reached  peak  magnitude  later  than after  ChAdOx1  and  AdC68  vaccination,  and  exhibited
a  slower  contraction  to  a memory  phenotype.  In cattle,  cellular  and  humoral  immune  responses  were
at least  equivalent,  if not  higher,  in magnitude  after  ChAdOx1  vaccination  compared  to  HAdV-5.  Though
we have  not  tested  protective  efﬁcacy  in  a  disease  model,  these  ﬁndings  have  important  implications  for
the  selection  of candidate  vectors  for  further  evaluation.  We  propose  that vaccines  based  on ChAdOx1  or
other Human  adenovirus  E serotypes  could  be  at  least  as  immunogenic  as  current  licensed  bovine  vaccines
based  on  HAdV-5.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Replication-defective recombinant adenoviruses are now
idely employed as vectors in the development of both human
nd veterinary vaccines [14,16,40]. Pre-existing neutralising anti-
odies to common human adenoviruses such as human adenovirus
erotype 5 (HAdV-5) may  have contributed to the lack of clinical
fﬁcacy of some vaccine vectors based on this serotype in human
rials [21]. Adenoviruses isolated from chimpanzees and other great
pes group phylogenetically within the human adenovirus species
32] but the seroprevalence of neutralising antibodies against these
erotypes in humans is considerably lower than against HAdV-5,
rompting the development of chimpanzee adenoviruses (ChAds)
s vaccine vectors [8,42]. ChAd vectors have primed unprecedented
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loor Borough Wing, Kings College London School of Medicine, Guy’s Hospital, Lon-
on SE1 9RT, UK. Tel.: +44 0 2071 885398.
E-mail address: matthew.dicks@kcl.ac.uk (M.D.J. Dicks).
ttp://dx.doi.org/10.1016/j.vaccine.2015.01.042
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
frequencies of antigen-speciﬁc CD8+ T cells in recent human clinical
vaccine trials [26,35,36].
For veterinary applications, HAdV-5 is still the most commonly
used human adenovirus serotype. Indeed, a new foot-and-mouth
disease virus (FMDV) vaccine based on this serotype has recently
been licensed in the United States for use in cattle [27]. Some
studies have successfully used serotypes originating from the tar-
get species, such as bovine adenovirus vectors in cattle, despite
pre-existing immunity to the vector [46]. However, the use of alter-
native adenovirus serotypes has yet to be fully explored.
Vector serotypes for both human and veterinary applications are
currently screened and selected largely on the basis of pre-clinical
studies in mice [8]. However, it remains unclear to what extent
these pre-clinical studies predict immunogenicity and efﬁcacy in
other mammalian species. In this study we  compared antigen-
speciﬁc immune responses elicited by vaccination with a HAdV-5
vector (Human adenovirus C, here referred to as species C) or a new
chimpanzee adenovirus vector ChAdOx1 [13] (Human adenovirus E,
here referred to as species E), in mice and cattle. In cattle, we tested
vectors encoding mycobacterial antigen 85A to represent bovine
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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uberculosis vaccine candidates in the target species [12,43]. This
s the ﬁrst time, to our knowledge, that a chimpanzee adenovirus
ector, or any vector derived from species E, has been tested in a
uminant species. In both species, we demonstrate differences in
he ability of vectors of different serotypes to elicit cellular and
umoral immune responses. Furthermore, by comparing studies
n laboratory animals and cattle, we demonstrate that compara-
ive immunogenicity studies in mice do not predict the hierarchy
f vector performance in a target species.
. Materials and methods
.1. Viral vectors
Propagation and titration of E1-E3-deleted recombinant HAdV-
, and chimpanzee adenovirus vectors AdC68 and ChAdOx1 on
EK293A cells (Invitrogen) has been described previously [13].
he design of vaccine antigen constructs has been described
reviously for TIPeGFP (an epitope string, TIP, fused to the N-
erminus of enhanced GFP) [1,9], and Inﬂuenza A virus NP + M1
fusion of nucleoprotein and matrix 1 protein sequences joined
y a glycine-proline linker) [25]. The Mycobacterium tuberculo-
is (TB) antigen 85A (Ag85A) construct used in this study was a
odon-optimized (for mammalian expression) version of the Ag85A
onstruct from TB vaccine candidate MVA-85A [22]. All recom-
inant vectors expressing TIPeGFP were titered by enumeration
f single GFP-positive HEK293 cells by epiﬂuorescent microscopy,
hile vectors expressing Ag85A and NP + M1 transgenes were
itered by immunostaining for the vaccine antigen as described pre-
iously [13]. For Ag85A, the monoclonal antibody SV5-PK1 (AbCam)
as used to detect a V5 tag fused to the C-terminus. For NP + M1,
onoclonal antibody GA2B against Inﬂuenza A matrix 1 protein
AbCam) was used. Viral particle estimates were performed by
pectrophotometric measurement of absorbance at 260 nm [20].
he ratios of estimated viral particles to infectious particles (P:I
atios) were as follows: HAdV-5 TIPeGFP, 15; ChAdOx1 TIPeGFP,
7; AdC68 TIPeGFP, 32; HAdV-5 Ag85A, 7; ChAdOx1 Ag85A, 27;
AdV-5 NP + M1,  12; ChAdOx1 NP + M1,  38.
.2. Mice and immunizations
Female BALB/c or C57BL/6J mice (Harlan, UK) above 6 weeks
f age were immunized intramuscularly (i.m.). Viral vectors were
ormulated in phosphate buffered saline (PBS, Sigma, UK) in a total
olume of 50 l and injected into the tibialis anterior muscle of
ach animal. All mouse procedures were performed in accordance
ith the terms of the UK Animals (Scientiﬁc Procedures) Act Project
icence (PPL 30/2414 or PPL 30/2889) and were approved by the
niversity of Oxford Animal Care and Ethical Review Committee.
.3. Mouse immunology
Spleen ex vivo interferon-gamma (IFN-) ELISpot was
erformed as described previously [19]. To measure vac-
ine antigen speciﬁc responses, cells were re-stimulated for
8–20 h with peptides (Supplementary Table 1) at a ﬁnal
oncentration of 1 g/mL. Spot forming cells (SFC) were mea-
ured using an automated ELISpot reader system (AID). Flow
ytometry on peripheral blood mononuclear cells (PBMC) was
erformed as described previously [37], except that peptide
e-stimulation was with 1 g/mL Pb9. All ﬂuorophore-conjugated
ntibodies were obtained from eBiosciences. Data were acquired
n a CyAn-ADP ﬂow cytometer (Dako) and analysed using FlowJo
Treestar). The program SPICE was used to generate graphical
epresentations of functional T cell responses using background-
educted data [31]. IgG endpoint ELISA was performed as described3 (2015) 1121–1128
previously [6,15] except plates were coated with recombinant GFP
protein (Millipore, UK) at 1 g/mL.
2.4. Cattle immunization
MHC-deﬁned, weight- and age-matched, conventionally reared
Friesian Holstein cattle from The Pirbright Institute’s (Pirbright)
MHC-deﬁned herd were vaccinated i.m. with viral vectors formu-
lated in PBS.
2.5. Cattle immunology
The following ﬂuorochrome-labeled mouse anti-bovine mono-
clonal antibodies (MAb) were used for ﬂow cytometry and
have been described previously [10]: CC30-APC/Cy5.5 (anti-CD4),
CC63-APC/Cy7 (anti-CD8), ILA-111–Alexa Fluor 610/PE (anti-
CD25), CC302-PE (anti-IFN-),  CC328-PE/Cy5.5 (anti-TNF-) and
Ab86-APC (anti-IL-2, Serotec). All antibodies were obtained from
Pirbright except where noted. Dead cells were gated out using
LIVE/DEAD aqua or propidium iodide (Invitrogen). Cells were
analyzed using an LSR Fortessa (Becton Dickinson), and stain-
ing assessed using FCS Express v4 (DeNovo Software). To detect
Ag85A-speciﬁc antibodies, 96-well plates (Costar) were coated
with 0.25 g of recombinant Ag85A (Lionex, Germany) for 2 h
at room temperature. Plates were washed with PBS/Tween and
blocked with Sea Block (Pierce) overnight, washed again with
PBS/Tween and dilutions of sera added to the plate. After 1 h,
the plates were washed and rabbit anti-bovine HRP (Serotec) was
added. The plates were incubated for 1 h, washed and TMB  sub-
strate (Pierce) added. After a 15 min  incubation the reactions were
stopped with 1 M H2SO4 and plates read on a Fluorostar Optima
(BMG Labtech, Germany).
2.6. Statistical analyses
Statistical analyses as indicated in ﬁgure legends were per-
formed using Prism (GraphPad Software, Inc.).
3. Results
3.1. HAdV-5 vectors elicit higher frequencies of vaccine antigen
speciﬁc T cells and antibodies in mice than AdC68 and ChAdOx1
based vectors
The ability of AdC68 and ChAdOx1 to induce transgene product
speciﬁc T cell and antibody responses was compared with HAdV-
5 in a series of dose-response experiments in mice with vectors
encoding the model antigen TIPeGFP [1]. Responses were assessed
after two weeks, identiﬁed previously to be at or near the peak
of the antigen speciﬁc CD8+ T cell response after adenovirus vector
administration [4,38]. HAdV-5 elicited higher frequencies of splenic
transgene product speciﬁc IFN-+ CD8+ and CD4+ T cell responses
than either of the chimpanzee adenovirus vectors in the 105–108
infectious units (ifu) dose range (Fig. 1A–C). The two  chimpanzee
adenovirus vectors induced similar CD8+ and CD4+ T cell frequen-
cies, consistent with our previous studies [13]. GFP-speciﬁc total
IgG antibody titers at the maximum 108 ifu dose were approxi-
mately two  orders of magnitude higher after HAdV-5 than after
ChAdOx1 or AdC68 (Fig. 1D). Titers were below the limit of detec-
tion after administration of either ChAd vector at doses lower than
108 ifu, though detectable titers were still observed after vacci-
nation with 106 ifu HAdV-5 (data not shown). Higher transgene
speciﬁc CD8+ T cell frequencies (at 106 ifu) and IgG endpoint titers
(at 108 ifu) were also observed in C57BL/6 mice after vaccination
with HAdV-5 TIPeGFP than with ChAdOx1 TIPeGFP (Supplementary
Fig. 1).
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Fig. 1. TIPeGFP speciﬁc IFN-+ T cell frequencies and antibody titers are higher after vaccination of mice with HAdV-5 than with AdC68 or ChAdOx1. BALB/c mice (4/group) were
immunised i.m. with 103–108 ifu of HAdV-5 TIPeGFP, AdC68 TIPeGFP, or ChAdOx1 TIPeGFP. Two  weeks post vaccination, splenic T cell responses against peptide epitopes
(A)  Pb9 (CD8+), (B) EGFP200–208 (CD8+) and (C) P15 (CD4+) were measured by IFN- ELISpot. Note that Pb9 and P15 epitopes are encoded within the TIP epitope string of
TIPeGFP. Graphs show mean response and SEM. Statistical analysis performed by two-way ANOVA with Bonferroni multiple comparison post-test. HAdV-5 versus AdC68;
****  p < 0.0001, *** p < 0.01, * p < 0.05. HAdV-5 verses ChAdOx1; ††††  p < 0.0001, †††  p < 0.001, ††  p < 0.01, †  p < 0.05. Overall ANOVA p-value for effect of vector <0.0001 in both
A  and B and <0.001 in C. Experiments with each vector were performed separately but included a group vaccinated with 106 ifu HAdV-5 TIPeGFP (approximately the ED50)
to  assess variability across experiments. No statistically signiﬁcant differences in responses were observed in this control group across individual experiments. (D) Anti-GFP
IgG  titers in the serum of the same mice measured by endpoint ELISA. Dashed lines in D indicate limit of detection of the assay. Statistical analysis performed by one-way
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cell frequencies were not signiﬁcantly different from those in theNOVA with Bonferroni post-test.
We  compared the CD8+ T cell responses elicited by HAdV-5
nd ChAdOx1 vectors encoding antigen constructs that have been
mployed in clinical trials: 85A [12,39,43] and NP + M1  [2]. IFN-
LISpot responses to the epitope P11 were of higher frequency after
AdV-5 85A administration than after ChAdOx1 85A at a dose of
08 ifu (p < 0.001) (Fig. 2A). Recombinant HAdV-5 NP + M1 elicited a
igher frequency of CD8+ T cells against the immunodominant epi-
ope NP147–155 than ChAdOx1 NP + M1  at a dose of 106 (p < 0.001)
ut not at doses of 107 or 108 ifu (Fig. 2B).
.2. The IFN-+ CD8+ T cell response after HAdV-5 vaccination
xhibits a later peak magnitude and contraction to memory than
fter AdC68 and ChAdOx1 vaccination
IFN-+ CD8+ T cell responses were monitored longitudinally
y intracellular cytokine staining (ICS) of peripheral blood mono-
uclear cells (PBMCs). Fig. 3A shows that, after an intramuscular
ose of 108 ifu, HAdV-5 TIPeGFP elicited a higher frequency of
b9 speciﬁc CD8+ T cell responses throughout the eight-week
uration of study than AdC68 and ChAdOx1 vectors express-
ng the same recombinant antigen. The peak magnitude of the
esponse after HAdV-5 administration was at the three-weektime-point, while the peak of the response after vaccination
with either ChAd vector was  at, or prior to, the two-week
time-point.
To assess memory phenotype, PBMCs were stained for the sur-
face markers CD62L and CD127 to deﬁne effector T cells (TEFF),
effector memory T cells (TEM), and central memory T cells (TCM) as
described previously [3] (Fig. 3B). Although the percentage of Pb9
speciﬁc CD8+ T cells displaying a TEFF phenotype decreased with
time in all three groups (consistent with a gradual differentiation to
TEM), HAdV-5 vaccination elicited an increased TEFF response com-
pared with AdC68 and ChAdOx1 up to 35 days post-vaccination.
However, 56 days post-vaccination, the relative proportions of TEFF
and TEM cells were comparable between all three groups, despite
the overall frequency of Pb9  speciﬁc IFN-+ CD8+ T cells being
statistically signiﬁcantly higher in the HAdV-5-vaccinated group
(Fig. 3B).
At a 100-fold lower dose (106 ifu), there was a trend towards
higher responses after HAdV-5 vaccination, but IFN-+ CD8+ TAdC68-vaccinated group (Fig. 3C). Memory phenotypes could not
be determined reliably owing to the limited size of the Pb9-speciﬁc
CD8+ T cell population.
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Fig. 2. HAdV-5 vaccination elicits higher transgene-product speciﬁc CD8+ T cell frequencies than ChAdOx1 with Ag85A and NP + M1  antigen constructs.  (A) BALB/c mice were
immunised intramuscularly with 106–108 ifu HAdV-5 85A or ChAdOx1 85A. Splenic T cell responses against epitope P11 were measured by IFN- ELISpot 2 weeks post-
vaccination. (B) BALB/c mice were immunised intramuscularly with 106–108 ifu HAdV-5 NP + M1 or ChAdOx1 NP + M1.  Splenic IFN- ELISpot responses against epitope
NP147-155 were measured two  weeks post vaccination. Mean response indicated, with error bars showing SEM. Statistical analysis performed by two-way ANOVA with
Bonferroni post-test. *** p < 0.001. Overall ANOVA p-value for effect of vector in A; p < 0.0001 B; p = 0.0026.
Fig. 3. IFN-+CD8+ T cell responses in mice after HAdV-5 vaccination peak later and are more durable than after AdC68 or ChAdOx1 vaccination. (A)–(B) BALB/c mice (6/group)
were  immunised with 108 ifu of HAdV-5 TIPeGFP, AdC68 TIPeGFP or ChAdOx1 TIPeGFP. Blood was  collected on days 12, 21, 36, and 56 post vaccination and Pb9  speciﬁc CD8+
IFN-+ T cell responses were measured by ICS. (A) Pb9 speciﬁc IFN-+CD8+ T cells as a percentage of total CD8+ T cells. Graphs display mean and SEM. Statistical analysis
by  two-way repeated measures ANOVA with Bonferroni post tests. HAdV-5 versus AdC68; *** p < 0.001, ** p < 0.01. HAdV-5 vs ChAdOx1; †††  p < 0.001 (B) Pb9 speciﬁc CD8+
IFN-+ T cells from the same mice as in A were identiﬁed as TEFF (CD127−CD62L−) or TEM (CD127+CD62L−), and the frequency of each subset was calculated as a percentage
o e tota
s e exp
† s.
3
v
wf  the total response. Frequencies of CD8+ TCM cells (CD127+CD62L+) were <1% of th
tatistical analysis by one-way ANOVA at each time point. ** p < 0.01, * p < 0.05. (C) Th
 p < 0.05. No statistically signiﬁcant differences between HAdV-5 and AdC68 group
.3. Cytokine secretion by vaccine antigen-speciﬁc CD8+ T cells
aries with time after vaccination with HAdV-5 versus ChAdOx1
Production of IFN-, TNF- and IL-2 by Pb9  speciﬁc CD8+ T cells
as assessed by ICS of PBMCs collected from the same animalsl IFN-+CD8+ T cell response at all time points. Stacked bars display mean and SEM;
eriment in A-B was repeated using doses of 106 ifu. HAdV-5 vs ChAdOx1; ††  p < 0.01,
used in the experiment shown in Fig. 3. Twelve days post vacci-
nation, a signiﬁcantly higher percentage of cells produced more
than one of these three cytokines after HAdV-5 vaccination than
after AdC68 or ChAdOx1 (Fig. 4). The percentage of cells express-
ing all three cytokines was also signiﬁcantly higher in the HAdV-5
M.D.J. Dicks et al. / Vaccine 33 (2015) 1121–1128 1125
Fig. 4. Proﬁle of cytokine expression by CD8+ T cells in mice after vaccination with
HAdV-5, ChAdOx1 and AdC68 vectors varies over time. ICS of Pb9-speciﬁc CD8+ T cells
(from the same experiment as Fig. 3A and B) for IFN-, IL-2, and TNF-. The pro-
portion of CD8+ T cells producing all three cytokines (orange), any combination of
two  cytokines (yellow), or any one cytokine only (green), in response to peptide
re-stimulation is show in the pie charts below. Statistical analyses on pie chart seg-
ments were performed by one-way ANOVA with Bonferroni post-tests. Segments
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Fig. 5. ChAdOx1 elicits higher transgene product speciﬁc T cell frequencies and IgG anti-
body  titers than HAdV-5 after intramuscular vaccination of cattle. Friesian Holstein
cattle (4/group) were immunized intramuscularly with 109 ifu of HAdV-5-85A or
ChAdOx1-85A. Blood samples were taken prior to immunization (week 0), and then
+ +rom ChAdOx1 and AdC68 groups that differ statistically signiﬁcantly in percentage
rom the corresponding segment in the HAdV-5 group are indicated. *** p < 0.001,**
 < 0.01, * p < 0.05. (For interpretation of the references to color in this ﬁgure legend,
he  reader is referred to the web version of this article.)
accinated group. At 21 days and 35 days post-vaccination, the
ercentage of cells expressing more than one cytokine remained
igniﬁcantly higher in the HAdV-5 vaccinated group. At 56 days
ost-vaccination, cytokine production proﬁles were comparable in
roups vaccinated with HAdV-5 and ChAdOx1, though an elevated
ercentage of cells expressing only one of the three cytokines was
aintained in the AdC68 vaccinated group (Fig. 4).
.4. ChAdOx1 elicits higher vaccine antigen speciﬁc T cell
requencies and antibody titers than HAdV-5 after intramuscular
dministration in cattle
Transgene product-speciﬁc T cell and antibody responses were
ompared after intramuscular injection of cattle with 109 ifu of
AdV-5 85A or ChAdOx1 85A vectors. Fig. 5A shows that 85A-
peciﬁc IFN-+ CD8+ T cell frequencies in the blood were highest
t the two-week time-point and were statistically signiﬁcantly
igher at this time-point after ChAdOx1 than after HAdV-5 vacci-
ation. 85A-speciﬁc IFN-+ CD4+ T cell responses followed a similar
inetic, albeit at lower frequencies than the CD8+ T cell responses,
nd the difference in frequency between vectors was  not statisti-
ally signiﬁcant at any time-point (Fig. 5B). 85A-speciﬁc serum IgGonce per week for a further six weeks. 85A-speciﬁc CD8 T cell (A) and CD4 T cell (B)
responses were measured by ICS. (C) Anti-85A IgG titers were assessed by endpoint
ELISA. Statistical analyses were performed by two-way repeated measures ANOVA
between the two  groups at each time point (**p < 0.01).
antibody titers continued to rise during the ﬁrst four weeks after
vaccination with both vectors (Fig. 5C). There was  a trend
toward higher anti-85A endpoint titers after ChAdOx1 vaccination
throughout the six-week duration of study, but statistical signiﬁ-
cance was reached at the two-week time-point only.
3.5. Cytokine production proﬁles of vaccine antigen speciﬁc CD8+
T cells are comparable after vaccination with HAdV-5 and
ChAdOx1 vectors in cattle
Production of IFN-, TNF- and IL-2 by 85A-speciﬁc CD8+ T cells
at the two-week and three-week time-points was  assessed by ICS
1126 M.D.J. Dicks et al. / Vaccine 33 (2015) 1121–1128
Fig. 6. Similar proﬁles of expression of three cytokines by CD8+ T cells in cattle vaccinated with HAdV-5 and ChAdOx1. ICS of 85A-speciﬁc CD8+ T cells (from the same experiment as
Fig. 5) for IFN-, IL-2, and TNF- at (A) two weeks or (B) three weeks post-vaccination. The proportion of CD8+ T cells producing all three cytokines (orange), any combination
of  two cytokines (yellow), or any one cytokine only (green), in response to peptide re-stimulation is shown in the pie charts. Bar charts indicate the percentages of total
CD8+ T cells secreting each combination of cytokines. Statistical analyses were performed by two-tailed t-tests between groups at each time-point; there were no signiﬁcant
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aifferences at either time-point. There were also no statistically signiﬁcant differen
etween the two and three week time points by one-way ANOVA. (For interpretatio
f  this article.)
f PBMCs collected from the same animals used in the experiment
hown in Fig. 5. The data shown in Fig. 6 indicate that the pro-
les of cytokine secretion of induced CD8+ T cells were similar
etween ChAdOx1 and HAdV-5 vaccinated animals at both these
ime points. There were no statistically signiﬁcant differences in
he percentages of 85A -speciﬁc CD8+ T cells producing one, two  or
hree cytokines between the two and three week time points.
. Discussion
This study revealed marked differences in the relative magni-
ude of transgene product speciﬁc T cell and antibody responses
licited by human and chimpanzee adenovirus vectors in two
ammalian species. In mice, HAdV-5 elicited T cell and antibody
esponses were higher in frequency than HAdV-E chimpanzee
denovirus vectors after intramuscular immunization. This rela-
ionship was observed using three antigens and in two  mouse
trains, suggesting that it is independent of the transgene or inbred
ouse strain. In cattle, an important target of veterinary vacci-
ation, a different relationship was observed; ChAdOx1 was as
mmunogenic as HAdV-5.
In mice, the observation that HAdV-5 vectors are more immuno-
enic than HAdV-E ChAd vectors is consistent with some published
tudies [7,8,29] but is not supported by others [28,30,38]. Disagree-
ents within the published literature may  result from differences
n the method used to determine vaccine dose [13]. Previous publi-
ations that are not consistent with the current study based vaccine
oses on viral particle estimation rather than on infectious titers.
The relationship between vector dose and the magnitude of
D8+ T cell responses varied considerably with different transgene
ntigens or epitopes, highlighting the importance of conductingthe percentages of 85A-speciﬁc CD8+ T cells producing one, two or three cytokines
e references to color in this ﬁgure legend, the reader is referred to the web version
comparative studies with multiple antigens across a range of doses
(Figs. 1 and 2). Mechanisms responsible for differences in the
magnitude of responses against different transgene antigens are
not well understood, but likely involve differences in the efﬁ-
ciency of antigen expression, peptide processing and presentation
on MHC  molecules, and the hierarchy of immunodominant epi-
topes present within both the viral vector and antigen construct
[33,45]. Previous studies comparing vectors in mice have typi-
cally administered vaccine doses in the order of 1010 viral particles
(equivalent to 5 × 108–5 × 109 ifu): at high doses, potential differ-
ences in immunogenicity between vectors may  be undetectable as
the magnitudes of responses reach a plateau. At a dose of 108 ifu,
Pb9 speciﬁc IFN-+ CD8+ T cell responses reached peak magnitude
later and were more durable after HAdV-5 vaccination compared
to ChAdOx1 and AdC68. However, at a 100-fold lower dose, the
magnitude and kinetic of the Pb9 speciﬁc CD8+ T cell response was
comparable between all three vectors (Fig. 3C) demonstrating a
dependence on vector dose, as previously suggested [29]. We  also
observed a later contraction to memory after HAdV-5, with a signiﬁ-
cantly higher proportion of CD8+ T cells retaining an effector (TEFF)
phenotype compared to the ChAd vectors. After eight weeks, the
proportion of TEFF relative to effector memory CD8+ T cells (TEM)
was similar for all three vectors, with a majority adopting a TEM
phenotype as observed previously [30,44].
Few previous studies have assessed the kinetics of vaccine
antigen speciﬁc T cell responses after adenovirus vector admin-
istration in cattle [43], and none to our knowledge have compared
the immunogenicity of vectors derived from members of different
human adenovirus species. In the current study, IFN-+ CD8+ and
CD4+ T cell responses were highest two  weeks post-vaccination
(Fig. 5), similar to observations in mice at the lower 106 ifu dose
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Fig. 3C). We  have not investigated the effect of dose on the timing
f peak CD8+ T cell frequency in cattle. Both HAdV-5 and ChAdOx1
nduced higher CD8+ T cell responses than CD4+ T cell responses,
n agreement with data in mice from this study and the consensus
n the literature [18,40]. Antibody titers continued to increase at
east six weeks after immunization of both vectors. The continued
levation could suggest that expression of the transgene product
s persistent, as in mice [41], although studies in cattle with dif-
erent antigens have observed antibody titers reaching a plateau
fter just two weeks [24] and a marked reduction in transgene
xpression at the injection site after 24 h [23]. The kinetics of CD8+
 cell, CD4+ T cell, and antibody responses were similar after HAdV-
 and ChAdOx1 vaccination, perhaps a function of the equivalence
n magnitude of these responses in cattle.
Recent studies have suggested that the ability of primed CD8+
nd CD4+ T cells to secrete multiple cytokines may  be an impor-
ant requirement for establishing a protective immune response
5,11,34]. In mice, a higher proportion of CD8+ T cells primed after
AdV-5 vaccination secreted two or more of the three cytokines
FN-, TNF- and IL-2 during the ﬁrst 35 days post vaccination
ompared to AdC68 and ChAdOx1 vaccinated animals (Fig. 4). In
attle, however, there were no statistically signiﬁcant differences
n cytokine secretion proﬁles between CD8+ T cells primed after
AdV-5 or ChAdOx1 vaccination (Fig. 6).
It is unclear whether the differences in frequency and pheno-
ype of vaccine antigen speciﬁc T cells observed in this study are
ue to differences in intrinsic vector biology including activation
f distinct innate signalling pathways, or simply due to differences
n the effective antigen dose delivered by HAdV-5 and ChAd vec-
ors. In mice, a previous study has shown that HAdV-5 elicits higher
ransgene expression in vivo after vaccination and within murine
Cs transduced in vitro compared to AdC68 [17]. In this study, the
inetic of the CD8+ T cell response in mice was dose dependent,
nd HAdV-5 responses at 106 ifu followed a similar kinetic to ChAd
nduced responses at 108 ifu. Persistence of antigen after HAdV-
 administration at the 108 ifu dose may  be responsible for the
bserved differences in kinetic and for the delayed contraction of
D8+ T cells to a TEM phenotype. Indeed, the proportion of transgene
peciﬁc CD8+ T cells expressing CD127 has been shown to decrease
ith increasing dose of HAdV-5 [29]. Differences in the proportion
f T cells secreting multiple cytokines may  also be a function of the
verall magnitude of the response. In cattle, CD8+ T cell responses
ere similar in magnitude between HAdV-5 and ChAdOx1, and no
igniﬁcant differences in T cell ‘multi-functionality’ were observed.
At present, selection of adenovirus vectors for human and vet-
rinary applications is largely based on comparative studies in mice
8]. Here, we show that the hierarchy of vector immunogenicity in
ice does not predict relative immunogenicity in cattle. Vectors
erived from members of species E, including those isolated from
himpanzees, represent promising alternatives to current HAdV-5
ased bovine vaccine platforms.
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